AURORA, ON, Nov. 7 /CNW/ - Helix BioPharma Corp. today announced that it has completed a private placement in Europe for gross proceeds of CAN $5,523,750. Helix issued 3,156,428 common shares and 3,156,428 common share purchase warrants in the European placement. Each common share purchase warrant entitles the holder to purchase one common share at a price of $2.45 until March 31st, 2008. Helix intends to use the net proceeds of the placement of $5.1 million (after finders’ fees) to fund the pre-clinical and clinical development of products in its pipeline and for working capital and general corporate purposes. This placement brings the total amount raised by way of private placement in the last 2 months to $9.5 million ($8.8 million net of finders’ fees).
